Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer

ERG Cooperates with Androgen Receptor in Regulating Trefoil Factor 3 in Prostate Cancer Disease Progression

(2015) David S. Rickman et al.   NEOPLASIA

Antibody-Based Detection of ERG Rearrangement-Positive Prostate Cancer

(2015) Kyung Park et al.   NEOPLASIA

Antibody-Based Detection ofERGRearrangements in Prostate Core Biopsies, Including Diagnostically Challenging Cases: ERG Staining in Prostate Core Biopsies

(2012) Scott A. Tomlins et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

(2012) A. Pettersson et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Rearrangement of the ETS genes ETV-1, ETV-4, ETV-5, and ELK-4 is a clonal event during prostate cancer progression

(2012) Zaki Shaikhibrahim et al.   HUMAN PATHOLOGY

TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation

(2012) Orla M. Casey et al.   PLoS One

Oncogene-mediated alterations in chromatin conformation

(2012) D. S. Rickman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk

(2012) F. Demichelis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Diagnostic Utility of Novel Immunohistochemical Marker ERG in the Workup of Prostate Biopsies With “Atypical Glands Suspicious for Cancer”

(2011) Huiying He et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

(2011) Sarah Minner et al.   CLINICAL CANCER RESEARCH

Prostate-specific antigen testing in Tyrol, Austria: prostate cancer mortality reduction was supported by an update with mortality data up to 2008

(2011) Willi Oberaigner et al.   International Journal of Public Health

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

(2011) A Marije Hoogland et al.   MODERN PATHOLOGY

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model

(2011) Orit Leshem et al.   PLoS One

Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA

(2011) S. A. Tomlins et al.   Science Translational Medicine

ERG gene rearrangement status in prostate cancer detected by immunohistochemistry

(2011) Sara Moscovita Falzarano et al.   VIRCHOWS ARCHIV

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Coordinate Transcriptional Regulation by ERG and Androgen Receptor in Fusion-Positive Prostate Cancers

(2010) Yu Chen et al.   CANCER CELL

An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression

(2010) Jindan Yu et al.   CANCER CELL

Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer

(2010) K. R. Rice et al.   CLINICAL CANCER RESEARCH

Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer

(2010) K. A. Leinonen et al.   CLINICAL CANCER RESEARCH

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease

(2010) Axel Heidenreich et al.   EUROPEAN UROLOGY

Clinical Implications of TMPRSS2-ERG Gene Fusion Expression in Patients With Prostate Cancer Treated With Radical Prostatectomy

(2010) José Rubio-Briones et al.   JOURNAL OF UROLOGY

Single Focus Prostate Cancer: Pathological Features and ERG Fusion Status

(2010) Sara M. Falzarano et al.   JOURNAL OF UROLOGY

Testing mutual exclusivity of ETS rearranged prostate cancer

(2010) Maria A Svensson et al.   LABORATORY INVESTIGATION

ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples

(2010) Yohei Miyagi et al.   MODERN PATHOLOGY

Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohort

(2010) Raquel Esgueva et al.   MODERN PATHOLOGY

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african-american and japanese patients

(2010) Cristina Magi-Galluzzi et al.   PROSTATE

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

(2010) B Furusato et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States

(2009) J.-M. Mosquera et al.   CLINICAL CANCER RESEARCH

Should Pathologists Routinely Report Prostate Tumour Volume? The Prognostic Value of Tumour Volume in Prostate Cancer

(2009) Tineke Wolters et al.   EUROPEAN UROLOGY

ERG Rearrangement Metastasis Patterns in Locally Advanced Prostate Cancer

(2009) Sven Perner et al.   UROLOGY

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

(2008) Georg Bartsch et al.   BJU INTERNATIONAL

Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications

(2008) J.-M. Mosquera et al.   CLINICAL CANCER RESEARCH

Cytopathology

(2008)   MODERN PATHOLOGY